Immunomodulators

A compound of formula (I)

• or a pharmaceutically acceptable salt thereof, wherein:
• A is
• wherein:
• denotes the point of attachment to the carbonyl group and denotes the point of attachment to the nitrogen atom;
• m is 1;
• w is 0
• R14 and R15 are hydrogen;
• R16a is selected from hydrogen and C1-C6 alkyl;
• R16 is
• —(C(R17a)2)—C(O)—NR50R51;
• wherein:
• each R17a is independently selected from hydrogen and C1-C6alkyl;
• one of R50 and R51 is selected from hydrogen and C1-C6alkyl and the other is selected from —(CH2)n′X, C1-C6alkyl, C3-C7cycloalkyl, heterocyclyl, and phenyl, wherein the cycloalkyl is optionally substituted with one, two, or three groups independently selected from C1-C3alkoxy, C1-C3alkyl, amino, cyano, and hydroxy, or;
• R50 and R51, together with the nitrogen atom to which they are attached, form a four-, five- six- or seven-membered saturated or unsaturated ring optionally containing one or two additional heteroatoms independently selected from nitrogen, oxygen, and sulfur;
• wherein said ring is optionally substituted with one, two, or three groups selected from C1-C6alkoxy, C1-C3alkyl, cyano, halo, haloC1-C3alkyl, hydroxy, hydroxy(C1-C3alkyl), —NR70R71, oxo, and phenyl;
• wherein the phenyl is further optionally substituted with one, two, or three groups independently selected from C1-C3alkoxy, cyano, and halo;
• n′ is 1-5;
• X is selected from —C≡CH,
• C2-C6alkoxymethyl, C1-C6alkoxycarbonylmethyl, C1-C6alkylsulfanylmethyl, C1-C6alkylsulfonylmethyl, azidomethyl, tert-butoxymethyl, C3-C7cycloalkyl, haloalkoxymethyl, halomethyl, heterocyclyl, hydroxymethyl, isopropoxymethyl, (NR70R71)methyl, phenyl, phenoxymethyl, and phenylsulfanylmethyl,
• one of R70 and R71 is selected from hydrogen, C1-C6alkyl, and hydroxyC2-C6alkyl and the other is selected from C1-C6alkoxycarbonyl, C1-C6alkylcarbonyl, C1-C6alkylsulfonyl, and hydroxyC2-C6alkyl;
• Rc, Rf, Rh, Ri, Rm, and Rn are hydrogen;
• Ra, Re, and Rj are hydrogen;
• Rb, Rk, and Rl are methyl;
• R1 is phenylmethyl wherein the phenyl is substituted with hydroxy;
• R2 is methyl;
• R3 is selected from —CH2C(O)NH2 and —CH2CO2H;
• R5 is selected from —CH2NH2, —CH2OH, and —CH2C(O)NH2;
• R6 is selected from —CH2CH(CH3)2, —(CH2)2CO2H, and (CH2)2C(O)NH2;
• R8 and R10 are —CH2(indolyl), wherein the indolyl is optionally substituted with —CH2CO2H;
• R9 is selected from hydrogen, —(CH2)2NH2, CH2OH, and —CH2C(O)NH2;
• R11 and R12 are —(CH2)3CH3;
• R13 is selected from methyl, —CH2CH(CH3)2, and —(CH2)2CO2H;
• Rd and R4, together with the atoms to which they are attached, form a pyrollidine ring;
• and
• Rg and R7, together with the atoms to which they are attached, form a pyrollidine ring, wherein said ring is optionally substituted with one hydroxy group.